Back

Quantifying Immune Checkpoint engagement in Patient Biopsies

Cacho Navas, C.; Camacho, L.; Aguero, J.; Batmunkh, B.; Gracia, J.; Eduardo de Andrea, C.; Martin Algarra, S.; Rementeria, M.; Miles, J.; Gumuzio, J.; Aguirre, F.; Parker, P. J.; Calleja, V.

2025-07-14 oncology
10.1101/2025.07.04.25330865 medRxiv
Show abstract

Immune checkpoint blockade (ICB) has emerged as a transformative approach in cancer treatment showing remarkable results on previously untreatable cancers. Nevertheless, a high percentage of patients fail to respond to treatment and often suffer strong immune related adverse events (irAE). Therefore, it becomes critical to identify with high confidence the patients who will respond to ICB using robust predictive biomarkers. To date patient stratification to treatment using current FDA approved biomarkers like PD-L1 TPS score has been poor. Hence, we propose that biomarkers assessing immune checkpoint functional state should better reflect the actual immune status of the tumour microenvironment (TME). Here, we describe a methodology for assessing the interaction of a panel of immune checkpoints in tissue and tumour samples using a quantitative spatial proteomics approach (QF-Pro). The functional immune profiling of tumours has the potential to provide a more profound understanding of the mechanisms put in place by the tumour to evade immune surveillance and offers a unique opportunity for the development of personalised immunotherapy regimens.

Published in Journal of Clinical Medicine · training set

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.